IDO2 and inflammatory bowel disease: Since the first study by Barceló-Batllori et al. [26], who identified increased indoleamine-2,3-dioxygenase expression in cytokine-treated colon epithelial cells by using proteomics technology, numerous studies have investigated proteomic changes in IBD.